k-pek and Abciximab Interactions

Interactions between k-pek(bismuth subsalicylate) and Abciximab (abciximab)

bismuth subsalicylate and abciximab (Moderate Drug-Drug)

MONITOR: Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function. Arterial puncture sites may be most problematic.

MANAGEMENT: It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.